Generating tolerogenic dendritic cells with neuropeptides

Human Immunology

Volumn 70, Issue 5, 2009, Pages 300-307

  Delgado, Mario ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Autoimmunity; Dendritic cell; Neuropeptide; Regulatory T cells; Tolerance

Indexed keywords

ALPHA INTERMEDIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERMEDIN; NEUROPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALLOTRANSPLANTATION; ANTIGEN SPECIFICITY; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL STIMULATION; CELL SUBPOPULATION; CELLULAR IMMUNITY; CLINICAL RESEARCH; DENDRITIC CELL; ENTERITIS; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SEPSIS; SJOEGREN SYNDROME; T LYMPHOCYTE ACTIVATION; TARGET CELL; TRANSPLANTATION TOLERANCE; UVEORETINITIS;

ANIMALS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; NEUROPEPTIDES; NEUROSECRETORY SYSTEMS; T-LYMPHOCYTES, REGULATORY;

EID: 65049084206     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.01.020     Document Type: Article

References (75)

1. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
2. Hackstein H., and Thomson A.W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 4 (2004) 24-34
3. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 109 (2003) 685-711
4. Mills K.H.G. Regulatory T cells: friend or foe in immunity to infection?. Nat Rev Immunol 4 (2004) 841-855
5. Bluestone J.A. Regulatory T-cell therapy: is it ready for the clinic?. Nat Rev Immunol 5 (2005) 343-349
6. Shevach E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25 (2006) 195-201
7. Rutella S., Danese S., and Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108 (2006) 1435-1440
8. Belkaid Y., and Oldenhoven G. Tuning microenvironments: induction of regulatory T cells with dendritic cells. Immunity 29 (2008) 362-371
9. Hawiger D., Inaba K., Dorsett Y., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194 (2001) 769-779
10. Roncarolo M.G., Levings M.K., and Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 193 (2001) F5-F9
11. Adorini L., Giarratana N., and Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 16 (2004) 127-134
12. Levings M.K., Gregori S., Tresoldi E., Cazzaniga S., Bonini C., and Roncarolo M.G. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 105 (2005) 1162-1169
13. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997) 737-742
14. Sato K., Yamashita N., Yamashita N., Baba M., and Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18 (2003) 367-379
15. Sato K., Yamashita N., Baba M., and Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 101 (2003) 3581-3589
16. Gonzalez-Rey E., Chorny A., and Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 7 (2007) 52-63
17. Sternberg E.M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 6 (2006) 318-328
18. Anderson P., and Delgado M. Endogenous anti-inflammatory neuropeptides and proresolving lipid mediators: a new therapeutic approach for immune disorders. J Cell Mol Med 12 (2008) 1830-1847
19. Blalock J.E. The immune system as the sixth sense. J Intern Med 257 (2005) 126-138
20. de Jong E.C., Vieira P.L., Kalinski P., and Kapsenberg M.L. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. J Leukocyte Biol 66 (1999) 201-204
21. Pettersson A., Ciumas C., Chirsky V., Link H., Huang Y.-M., and Xiao B.-G. Dendritic cells exposed to estrogen in vitro exhibit therapeutic effects in ongoing experimental allergic encephalomyelitis. J Neuroimmunol 156 (2004) 58-65
22. Penna G., Guiarratana N., Amuchastegui S., Mariani R., Daniel K.C., and Adorini L. Manipulating dendritic cells to induce regulatory T cells. Microbes Infect 7 (2005) 1033-1039
23. Gonzalez-Rey E., and Delgado M. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?. Trends Pharmacol Sci 28 (2007) 482-491
24. Gonzalez-Rey E., Chorny A., Varela N., Del Moral R.G., and Delgado M. Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Ann Rheum Dis 66 (2007) 582-588
25. Namba K., Kitaichi N., Nishida T., and Taylor A.W. Induction of regulatory T cells by the immunomodulating cytokines α-melanocyte stimulating hormone and transforming growth factor-β2. J Leukocyte Biol 72 (2002) 946-952
26. Nishida T., and Taylor A.W. Specific aqueous humor factors induce activation of regulatory T cells. Invest Ophthalmol Vis Sci 40 (1999) 2268-2274
27. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., and Delgado M. Vasoactive intestinal peptide induces CD4+CD25+ regulatory T cells with therapeutic effect on collagen-induced arthritis. Arthritis Rheum 54 (2006) 864-876
28. Fernandez-Martin A., Gonzalez-Rey E., Chorny A., Ganea D., and Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol 36 (2006) 318-326
29. Gonzalez-Rey E., Chorny A., Varela N., O'Valle F., and Delgado M. Therapeutic effect of urocortin on collagen-induced arthritis by downregulating inflammatory and Th1 response and inducing regulatory T cells. Arthritis Rheum 56 (2007) 531-543
30. Gonzalez-Rey E., Chorny A., O'Valle F., and Delgado M. Adrenomedullin protects from experimental arthritis by downregulating inflammation and Th1 response and inducing regulatory T cells. Am J Pathol 170 (2007) 263-271
31. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., and Delgado M. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut 55 (2006) 824-832
32. Gonzalez-Rey E., Chorny A., and Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 130 (2006) 1707-1720
33. Delgado M., and Ganea D. Cutting edge: is vasoactive intestinal peptide a type 2 cytokine?. J Immunol 166 (2001) 2907-2912
34. Lipton J.M., and Catania A. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol Today 18 (1997) 140-145
35. Banner K.H., and Trevethick M.A. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 25 (2004) 430-436
36. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109 (2006) 366-368
37. Luger T.A., Scholzen T.E., Brzoska T., and Bohm M. New insights into the functions of α-MSH and related peptides in the immune system. Ann NY Acad Sci 994 (2003) 133-140
38. Delgado M., Reduta A., Sharma V., and Ganea D. VIP/PACAP oppositely affect immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity of CD4+ T cells. J Leukocyte Biol 75 (2004) 1122-1130
39. Delgado M., and Gonzalez-Rey E. Vasoactive intestinal peptide inhibits cycloxygenease 2 expression in activated macrophages, microglia and dendritic cells. Brain Behav Immun 22 (2008) 35-41
40. Delgado M., Gonzalez-Rey E., and Ganea D. VIP/PACAP preferentially attract Th2 versus Th1 cells by differentially regulating the production of chemokines by dendritic cells. FASEB J 18 (2004) 1453-1455
41. Delgado M., Leceta J., Gomariz R.P., and Ganea D. VIP and PACAP stimulate the induction of Th2 responses by upregulating B7.2 expression. J Immunol 163 (1999) 3629-3635
42. Delgado M., Leceta J., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 16 (2002) 1844-1846
43. Voice J.K., Dorsam G., Lee H., Kong Y., and Goetzl E.J. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible VIP receptor. FASEB J 15 (2001) 2489-2496
44. Goetzl E.J., Voice J.K., Shen S., Dorsam G., Kong Y., West K.M., et al. Enhanced delayed-type hypersensitivity and diminished immediate type hypersensitivity in mice lacking the inducible VPAC(2) receptor for VIP. Proc Natl Acad Sci USA 98 (2001) 13854-13859
45. Voice J., Donnelly S., Dorsam G., Dolganov G., Paul S., and Goetzl E.J. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 170 (2003) 308-314
46. Delgado M., Gonzalez-Rey E., and Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 175 (2005) 7311-7324
47. Gonzalez-Rey E., Chorny A., Fernandez-Martin A., Ganea D., and Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 107 (2006) 3632-3638
48. Jarvis L.B., Matyszak M.K., Duggleby R.C., Goodall J.C., Hall F.C., and Gaston J.S.H. Autoreactive human peripheral blood CD8+ T cells with a regulatory phenotype and function. Eur J Immunol 35 (2005) 2896-2908
49. Filaci G., Fravega M., Negrini S., Procopio F., Fenoglio D., Rizzi M., et al. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol 65 (2004) 142-156
50. Wakkach A., Fournier N., Brun V., Breittmayer J.P., Cottrez F., and Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18 (2003) 605-617
51. Martin E., O'Sullivan B., Low P., and Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 18 (2003) 155-167
52. Yang J., Bernier S.M., Ichim T.E., Li M., Xia X., Zhou D., et al. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kB signaling through inhibition of IKK activity. J Leukocyte Biol 74 (2003) 438-447
53. Ouaaz F., Li M., and Beg A.A. A critical role for the RelA subunit of nuclear-factor-kappaB in regulation of multiple immune response genes and in Fas-induced cell death. J Exp Med 189 (1999) 999-1004
54. D'Ambrosio D., Sinigaglia F., and Adorini L. Special attractions for suppressor T cells. Trends Immunol 24 (2003) 122-126
55. Fabricius D., O′Dorisio M.S., Blackwell S., and Jahsdorfer B. Human plasmacytoid dendritic cell function: Inhibition of IFN-a secretion and modulation of immune phenotype by vasoactive intestinal peptide. J Immunol 177 (2006) 5920-5927
56. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23 (2005) 275-306
57. Blanco P., Palucka A.K., Gill M., Pascual V., and Banchereau J. Induction of dendritic cell differentiation by IFN-a in systemic lupus erythematosus. Science 294 (2001) 1540-1543
58. Pestka S., Krause C.D., and Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev 202 (2004) 8-32
59. Penna G., Sozzani S., and Adorini L. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 167 (2001) 1862-1866
60. Delgado M., Chorny A., Gonzalez-Rey E., and Ganea D. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J Leukocyte Biol 78 (2005) 1327-1338
61. Taylor A., and Namba K. In vitro induction of CD25+CD4+ regulatory T cells by the neuropeptide α-melanocyte stimulating hormone (α-MSH). Immunol Cell Biol 79 (2001) 358-367
62. Zheng S.G., Wang J.H., Gray J.D., Soucier H., and Horwitz D.A. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J. Immunol 172 (2004) 5213-5221
63. Svensson M., Maroof A., Ato M., and Kaye P.M. Stromal cells direct local differentiation of regulatory dendritic cells. Immunity 21 (2004) 805-816
64. Ardavin C. Origin, precursors and differentiation of mouse dendritic cells. Nat Rev Immunol 3 (2003) 582-590
65. Chomarat P., Banchereau J., Davoust J., and Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 1 (2000) 510-514
66. Delneste Y., Charbonnier P., Herbault N., Magistrelli G., Caron G., Bonnefoy J.Y., et al. Interferon-γ switches monocyte differentiation from dendritic cells to macrophages. Blood 101 (2003) 143-150
67. Wang J., Zhao R., Zhang F., Li J., Huo B., Cao Y., et al. Control of allograft rejection in mice by applying a novel neuropeptide, cortistatin. Adv Ther 25 (2008) 133-141
68. Chorny A., Gonzalez-Rey E., Fernandez-Martin A., Pozo D., Ganea D., and Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci USA 102 (2005) 13562-13567
69. Gonzalez-Rey E., and Delgado M. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology 131 (2006) 1799-1811
70. Wood K.J., and Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3 (2003) 199-210
71. Chorny A., Gonzalez-Rey E., Fernandez-Martin A., Ganea D., and Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells that can prevent acute graft-versus-host disease while maintain graft-versus-tumor. Blood 107 (2006) 3787-3794
72. Juarranz Y., Gutierrez-Canas I., Santiago B., Carrion M., Pablos J.L., and Gomariz R.P. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 58 (2008) 1086-1095
73. Delgado M., Robledo G., Rueda B., Varela N., O'Valle F., Hernandez-Cortes P., et al. Genetic association of vasoactive intestinal peptide with rheumatoid arthritis. Altered expression and signal in immune cells. Arthritis Rheum 58 (2008) 1010-1019
74. Sun W., Hong J., Zang Y.C., Liu X., and Zhang J.Z. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol 18 (2006) 1691-1700
75. Bangale Y., Karle S., Planque S., Zhou Y.X., Taguchi H., Nishiyama Y., et al. VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J 17 (2003) 628-635